All AbMole products are for research use only, cannot be used for human consumption.
Moxifloxacin possibly stimulates lipid peroxidation and enhances phagocytosis, as depicted by MDA production and survival prolongation, without being toxic as depicted by white blood cell count. Moxifloxacin-containing triple therapy, a recommended second-line treatment for initial concomitant or sequential therapy failure, had insufficient efficacy. Moxifloxacin reportedly exhibits immunomodulatory properties, but experimental evidence in pneumonia is lacking. Moxifloxacin has limited phototoxic potential. In clinical trials, moxifloxacin had clinical success rates of 88-97% and bacteriologic eradication rates of 90-97%. Moxifloxacin is a safe and effective antimicrobial that will be useful for treating acute sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia.
| Molecular Weight | 401.43 |
| Formula | C21H24FN3O4 |
| CAS Number | 151096-09-2 |
| Solubility (25°C) | DMSO |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related Topoisomerase Products |
|---|
| XR11576
XR11576 (MLN576) is an orally active inhibitor of topoisomerase I and II. |
| Silatecan
Silatecan (AR-67; DB 67) is a Camptothecin analogue with improved stability and lipophilicity. |
| 9-Hydroxyellipticine hydrochloride
9-Hydroxyellipticine hydrochloride is a inhibitor of Topo II and RyR. |
| Moxifloxacin-d4
Moxifloxacin-d4 |
| F14512
F14512 is a polyamine-containing inhibitor of DNA topoisomerase II with a broad spectrum of antitumor activities. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
